Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 6:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,607 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Diseases/Diagnoses Clear all
Completed No phase listed Observational

Tryptophan Metabolism in Human Brain Tumors

NCT02367469
View directory record Official record
Conditions
Brain Tumors
Interventions
Not listed
Lead sponsor
Wayne State University
Other
Eligibility
13 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Jul 22, 2026, 6:55 PM EDT
Active, not recruiting Phase 2 Interventional

Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM

NCT04052880
View directory record Official record
Conditions
Newly Diagnosed Multiple Myeloma
Interventions
Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Ixazomib
Drug
Lead sponsor
Larysa Sanchez
Other
Eligibility
70 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Jul 22, 2026, 6:55 PM EDT
Active, not recruiting Early Phase 1 Interventional

Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery

NCT03943173
View directory record Official record
Conditions
BRCA-Mutated Ovarian Carcinoma, BRCA1 Gene Mutation, BRCA2 Gene Mutation, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IIIA Fallopian Tube Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Primary Peritoneal Cancer AJCC v8, Stage IIIA1 Fallopian Tube Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Fallopian Tube Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Fallopian Tube Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Primary Peritoneal Cancer AJCC v8, Stage IIIC Fallopian Tube Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8
Interventions
Chemotherapy, Olaparib, Therapeutic Conventional Surgery
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jul 22, 2026, 6:55 PM EDT
Completed Not applicable Interventional

Simulation-Free Hippocampal-Avoidance Whole Brain Radiotherapy Using Diagnostic MRI-Based and Cone Beam Computed Tomography-Guided On-Table Adaptive Planning in a Novel Ring Gantry Radiotherapy Device

NCT05096286
View directory record Official record
Conditions
Intracranial Metastatic Disease From Any Solid Malignancy
Interventions
Ethos Therapy
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Jul 22, 2026, 6:55 PM EDT
Not listed Phase 3 Interventional Results available

Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT00651261
View directory record Official record
Conditions
Leukemia
Interventions
cytarabine, daunorubicin, midostaurin, placebo, dexamethasone acetate
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 59 Years
Enrollment
717 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
170
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 126 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Jul 22, 2026, 6:55 PM EDT
Completed Phase 2 Interventional

Etoposide Plus Radiation Therapy Followed by Combination Chemotherapy in Treating Children With Newly Diagnosed Advanced Medulloblastoma

NCT00003573
View directory record Official record
Conditions
Brain Tumors, Central Nervous System Tumors
Interventions
filgrastim, cisplatin, cyclophosphamide, etoposide, vincristine sulfate, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 21 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2008
U.S. locations
94
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Jul 22, 2026, 6:55 PM EDT
Withdrawn Not applicable Interventional

Biomarkers in Blood Samples From Young Patients With Newly Diagnosed Brain Tumors Undergoing Standard Radiation Therapy and Chemotherapy

NCT01233479
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
systemic chemotherapy, laboratory biomarker analysis, therapeutic surgical procedure, radiation therapy
Drug · Other · Procedure + 1 more
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
4 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2019 · Synced Jul 22, 2026, 6:55 PM EDT
Completed Not applicable Interventional

PET Scans in Diagnosing Primary or Recurrent Cervical Cancer in Patients Who Are Undergoing Surgery

NCT00003429
View directory record Official record
Conditions
Cervical Cancer
Interventions
biopsy, computed tomography, positron emission tomography, fludeoxyglucose F 18
Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2015 · Synced Jul 22, 2026, 6:55 PM EDT
Not listed Phase 3 Interventional

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer

NCT00045968
View directory record Official record
Conditions
Glioblastoma Multiforme, Glioblastoma, GBM, Grade IV Astrocytoma, Glioma, Brain Cancer, Brain Tumor
Interventions
Dendritic cell immunotherapy
Drug
Lead sponsor
Northwest Biotherapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
71
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Castro Valley, California + 56 more
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Jul 22, 2026, 6:55 PM EDT
Terminated Not applicable Interventional

Diagnostic Endoscopic Exploration for Pancreatic Head Mass

NCT00816179
View directory record Official record
Conditions
Pancreatic Head Mass
Interventions
Transgastric diagnostic endoscopic peritoneoscopy
Procedure
Lead sponsor
Jeffrey Hazey
Other
Eligibility
18 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 2, 2014 · Synced Jul 22, 2026, 6:55 PM EDT
Recruiting Not applicable Interventional

Non-Invasive Quantification of Liver Health in NASH (N-QUAN)

NCT04054310
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
Liver Multi Scan
Diagnostic Test
Lead sponsor
Perspectum
Industry
Eligibility
18 Years to 75 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
7
States / cities
Chandler, Arizona • Chicago, Illinois • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jul 22, 2026, 6:55 PM EDT
Not listed No phase listed Observational

Adherence to Preventive Care for Cervical Cancer

NCT02406391
View directory record Official record
Conditions
Cervical Cancer, Cervical Precancer, Adherence
Interventions
Not listed
Lead sponsor
Brookdale University Hospital Medical Center
Other
Eligibility
21 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
Brooklyn, New York • El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Jul 22, 2026, 6:55 PM EDT
Completed No phase listed Observational

The ADAPT Study: Assessment of the DiAgnostic Performance of DeepVessel FFR in SuspecTed Coronary Artery Disease

NCT04828590
View directory record Official record
Conditions
Coronary Artery Disease, Myocardial Ischemia
Interventions
No intervention
Other
Lead sponsor
Keya Medical
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Fort Lauderdale, Florida • Kansas City, Kansas • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Jul 22, 2026, 6:55 PM EDT
Not yet recruiting Phase 2 Interventional

ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma

NCT07247097
View directory record Official record
Conditions
Multiple Myeloma, Newly Diagnosed Multiple Myeloma, Transplant Ineligible, Newly Diagnosed Multiple Myeloma (NDMM)
Interventions
Elranatamab (PF-06863135), Daratumumab and Hyaluronidase-fihj, Lenalidomide, Bortezomib for Injection, Dexamethasone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jul 22, 2026, 6:55 PM EDT
Withdrawn Phase 2 Interventional

Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment

NCT02269579
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS)
Interventions
CPX-351
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
5
States / cities
Los Angeles, California • Gainesville, Florida • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Jul 22, 2026, 6:55 PM EDT
Terminated Not applicable Interventional

Evaluating the Effect of Perioperative Caloric Restriction Program on Perioperative Outcomes in Patients With Obesity and Endometrial Cancer

NCT02665962
View directory record Official record
Conditions
Obese, Endometrial Cancer
Interventions
Perioperative Caloric Restriction Program
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Jul 22, 2026, 6:55 PM EDT
Terminated Phase 3 Interventional

Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease

NCT00282503
View directory record Official record
Conditions
Acute Graft-versus-Host Disease
Interventions
Methoxsalen+ECP, Methylprednisolone, Ecp
Drug · Procedure
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
5
States / cities
Gainesville, Florida • Ann Arbor, Michigan • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2017 · Synced Jul 22, 2026, 6:55 PM EDT
Recruiting Phase 2Phase 3 Interventional

PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores

NCT03495427
View directory record Official record
Conditions
Prostate Cancer, Recurrent Prostate Cancer
Interventions
F-DCFPyL Injection, PSMA PET
Drug · Diagnostic Test
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Jul 22, 2026, 6:55 PM EDT
Completed Phase 2 Interventional

Radiation Therapy and Tamoxifen in Treating Adults With Newly Diagnosed Supratentorial Glioblastoma Multiforme

NCT00006388
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
tamoxifen citrate, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
237
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 184 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Jul 22, 2026, 6:55 PM EDT
Recruiting No phase listed Observational

Phase I Human Analytics (HALO) Study

NCT05423860
View directory record Official record
Conditions
Cardiovascular Diseases, Cancer, Dementia, Traumatic Brain Injury
Interventions
no interventions will be performed (observational)
Other
Lead sponsor
HALO Diagnostics
Industry
Eligibility
45 Years to 90 Years · Male only
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2037
U.S. locations
1
States / cities
Indian Wells, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Jul 22, 2026, 6:55 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Atypia of Undetermined Significance (AUS) / Follicular Lesion of Undetermined Significance (FLUS)

NCT03224754
View directory record Official record
Conditions
Diagnoses Disease
Interventions
Determination of risk of malignancy of these thyroid lesions
Behavioral
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated May 10, 2018 · Synced Jul 22, 2026, 6:55 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of GTS21 in Adults With Attention-deficit Hyperactivity Disorder

NCT00419445
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
GTS21/Placebo
Drug
Lead sponsor
CoMentis
Industry
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2010 · Synced Jul 22, 2026, 6:55 PM EDT
Completed Not applicable Interventional

The Biodistribution and Potential Diagnostic Ability of 18F FACBC in Patients With Head and Neck, Breast, and Prostate Cancer

NCT00605488
View directory record Official record
Conditions
Breast Cancer, Head and Neck Cancer, Prostate Cancer
Interventions
novel PET tracer FACBC
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2017 · Synced Jul 22, 2026, 6:55 PM EDT
Terminated Phase 2 Interventional Results available

Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)

NCT00612066
View directory record Official record
Conditions
Cushing's Disease
Interventions
rosiglitazone maleate
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Jul 22, 2026, 6:55 PM EDT